ASX · RAC.AX
Race Oncology Limited
A$1.55-A$0.01 (-0.32%)
Race Oncology Limited’s quoted price sits in the lower half of its reported 52-week range, 59.23% below the high.
Loading market information…
ASX · DXB.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Dimerix Limited’s quoted price sits in the lower half of its reported 52-week range, 68.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dimerix Limited’s forward annual dividend is A$1.22 per share, paid annual. The forward yield is 578.64% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Dimerix Limited’s next earnings report is currently expected on Mar 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dimerix Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$0.00-100.0% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$1.55-A$0.01 (-0.32%)
Race Oncology Limited’s quoted price sits in the lower half of its reported 52-week range, 59.23% below the high.
A$0.04-A$0.00 (-2.33%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.46-A$0.03 (-6.12%)
Nyrada Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.06% below the high.
A$0.36+A$0.03 (+9.09%)
Recce Pharmaceuticals Ltd’s quoted price sits in the lower half of its reported 52-week range, 50.68% below the high.
A$0.29-A$0.04 (-10.77%)
Island Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 53.97% below the high.
A$0.27+A$0.01 (+1.92%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 66.24% below the high.
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
A$0.08-A$0.01 (-5.62%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 69.45% below the high.
